Exploring the anti-breast cancer (against MCF-7 Cell Line) potentials of uracil substituted hippuric acid based 1,3,4-thiadiazole compound

Abstract

In the previous research done, uracil moiety substituted hippuric acid containing 1,3,4-thiadiazole scaffold was rationally designed, synthesized, and screened for anti-diabetic activity using the streptozotocin-induced hyperglycemic method in Swiss albino rats. In the current research, the same compound N-((5-(((2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl)amino)-1,3,4-thiadiazol-2-yl)methyl)benzamide was screened against MCF-7 breast cancer cell line utilizing the Sulforhodamine B (SRB) assay and further the IC50 value was established in comparison with capecitabine, the standard drug. The study highlighted a notable anti-breast cancer activity against breast cancer cell line MCF-7 by the uracil substituted hippuric acid based 1,3,4-thiadiazole compound. The activity of the compound was although not analogous to the positive control drug capecitabine, as indicated by the IC50 value. The combination of hippuric acid, 1,3,4-thiadiazole, and uracil produced synergistic activity which arrested cell proliferation. The study will certainly open new avenues and provide direction towards anti-proliferative research by the rational hybridization of small molecules.